Abstract:T he ability of grapefruit juice to increase drug levels in blood was accidentally discovered during a pharmacokinetic study designed to evaluate an interaction between felodipine (Plendil), a drug prescribed for treatment of hypertension, and ethanol. Double-strength grapefruit juice was used to mask the taste of the ethanol in this randomized, crossover, double-blind study. A nonintoxicating dose of ethanol or placebo was administered to subjects, followed by a 5-mg dose of felodipine. For both study arms, serum felodipine concentrations were noted to be several times greater than that previously reported at that same dose when grapefruit juice was not used. It was then recognized that this finding was possibly due to a pharmacodynamic interaction between grapefruit juice and felodipine. Since this observation, much research has focused on the mechanisms of drugYgrapefruit juice interactions and the medications that interact with the juice. Grapefruit juice is very popular, purchased by 21% of all households in the United States. The United States produces nearly 40% of the world’s supply of grapefruit, with Florida being the largest producer, averaging 2 million tons of fruit per year. Grapefruit is endorsed by the American Heart Association as a ‘‘heart-healthy food’’ because it contains compounds that may reduce the formation of artherosclerotic plaques. It may also inhibit cancer cell proliferation. The compounds in grapefruit juice, however, may also be responsible for clinically significant drug interactions with numerous prescription medications, thus raising potential concern regarding whether it should be consumed at the same time with them. Its effects are most pronounced on cyclosporine, some calcium antagonists, and the hydroxymethylglutarylYcoenzyme A reductase inhibitors. In oral doses of approximately 8 oz, grapefruit juice increases the serum concentrations of these drugs from 1.5to 15-fold. For some drugs such as felodipine and nicardipine, the increased drug concentrations could potentially be associated with an increased frequency of dose-dependent adverse effects, although actual reports of toxicity with drugYgrapefruit juice interactions have been rare. The drugYgrapefruit juice interaction is caused by inhibition of the intestinal cytochrome P-450 enzyme system, particularly cytochrome P450 3A4 (CYP450 3A4), by 1 or more of the components in grapefruit juice. Many active components in grapefruit juice have been evaluated for potentially causing this interaction, including flavonoids such as naringenin, naringin, quercetin, and kaempferol, and nonflavonoids such as 6,7-dihydroxybergamottin, bergaptol, and 6,7-epoxybergamottin. Naringin, the glycoside of naringenin, is the most abundant flavonoid in grapefruit juice, constituting up to 10% of its dry weight. Naringin is not found in other citrus or fruit juices and is responsible for the distinctive smell and bitter taste of grapefruit juice. Naringin exerts no effect on the activity of the CYP450 system in vitro, but in vivo, its metabolite, naringenin, is a potent inhibitor of both the CYP 3A and CYP 1A2 isoforms. However, most research suggests the furanocoumarin 6,7-didydroxybergamottin and/or its parent compound bergamottin to be the major CYP 3A4 inhibitors found in grapefruit juice.

The Effect of Grapefruit Juice on Clinical Drug

Food-drug Interactions Precipitated by Fruit Juices Other Than Grapefruit Juice: an Update Review

Furanocoumarin Profiles and Inhibitory Effects on Cytochrome P450 Activity of Whole Citrus Fruit

Effects of Edible Whole Citrus Fruits on Endogenous Antioxidant Enzymes of HepG2 Cells

An Updated Review on Chemical Compositions, Biological Capabilities, and Clinical Benefits of Cranberries

Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance

Research Development of CYP3A4 Inhibitors in Grapefruit

Interaction between grapefruit juice and calcium channel blockers

A REVIEW: EXTRACTION OF THE BIOACTIVE COMPONENTS AND THE FUNCTIONS OF GRAPEFRUIT

Clinically Significant Grapefruit Juice-Drug Interactions

Effects of Food Matrix Elements (dietary Fibres) on Grapefruit Peel Flavanone Profile and on Faecal Microbiota During in Vitro Fermentation

Effects of Three Kinds of Juice of Mandarinorange on Pharmacokinetics of Atorvastatin in Healthy Volunteers

Influences of grapefruit juice on the pharmacokinetics of carbamazepine in rabbits

The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats.

Potential Metabolic Drug-Drug Interaction of Citrus aurantium L. ( Rutaceae ) Evaluating by Its Effect on 3 CYP450.

EFFECTS OF CITRUS FRUITS ON BLOOD LIPID LEVELS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Impact of citrus fruit and hesperidin intake on multiple health outcomes:An umbrella review

Review of phytochemical and nutritional characteristics and food applications of Citrus L. fruits

Research Advances in Citrus Polyphenols: Green Extraction Technologies, Gut Homeostasis Regulation, and Nano-Targeted Delivery System Application

Effects and Mechanisms of Fruit and Vegetable Juices on Cardiovascular Diseases

Effects of Simulated Gastrointestinal Digestion on Antioxidant Activities of Individual and Mixed Fruits